Arbutus Biopharma Corp (Arbutus) is a clinical-stage biopharmaceutical company that aims to develop proprietary drug delivery systems and product candidates for the treatment of chronic hepatitis B infection (HBV).

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Arbutus has undertaken research and development (R&D) initiatives focused on pursuing a functional cure for chronic hepatitis B (cHBV). The company is advancing the clinical development of imdusiran and AB-101, while also ceasing all discovery efforts and discontinuing the IM-PROVE III clinical trial. The company has also discontinued its coronavirus and AB161 programs and reduced research activities and preclinical study costs for AB-101. The R&D unit of Arbutus is responsible for managing clinical development activities, including personnel expenses, fees paid to clinical research organizations and contract manufacturers, as well as other third-party expenses. Its IM-Prove I (cHBV Program Imdusiran (IDR) RNAi Therapeutic (Subcutaneous), a combination of imdusiran + Peg-IFNa-2a + NA is in Phase II trial; the IM-PROVE II Combo trial (imdusiran + nivolumab + NA + VTP-300) is also in Phase II trial; and Immunotherapy Program AB-101 PD-L1 Inhibitor (Oral) is in Phase I trial. In FY2025, the company spent US$25.4 million on R&D, which declined 53.2% YoY.